SciSparc
SciSparc Ltd. is an Israeli clinical-stage pharmaceutical company (NASDAQ: SPRC) developing cannabinoid-based drug candidates — SCI-110, SCI-210, and SCI-160 — for neurological, autism, and pain indications, with CannAmide nutraceutical sales in Canada and recent expansion into MUSE GERD devices and CliniQuantum quantum-simulation software via its NeuroThera Labs subsidiary.
- Company typePublic
- Founded2020
- HeadquartersGiv'atayim, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SciSparc does
SciSparc Ltd. is an Israeli clinical-stage pharmaceutical company (NASDAQ: SPRC; headquartered in Giv'atayim) developing proprietary cannabinoid-based drug candidates for neurological and pain indications. Its lead platforms, SCI-110 (Dronabinol combined with the proprietary CannAmide PEA formulation) and SCI-210 (CBD combined with CannAmide), are in clinical trials for Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's-related agitation, and Autism Spectrum Disorder; SCI-160, a synthetic CB2 receptor agonist (HU-433) synthesized by Prof. Raphael Mechoulam, is in pre-clinical pain studies. SciSparc also markets CannAmide as a Health Canada–licensed nutraceutical (400mg tablets) and, via 2025–2026 acquisitions, has expanded into medical devices (MUSE endoscopic GERD system, acquired from Xylo Technologies) and quantum-simulation software for clinical-trial analytics (CliniQuantum, acquired indirectly through NeuroThera Labs).
Revenue is essentially pre-commercial: drug candidates are not FDA-approved, CannAmide is the only commercial product with limited Canadian nutraceutical sales, and the MUSE device is pre-launch. Value-creation mechanics depend on FDA/regulatory milestones, partnership/licensing deals, or future device commercialization in North America, Europe, and Latin America. The corporate structure is complex following the October 2025 transfer of the pharmaceutical portfolio into a controlling ~75% stake in NeuroThera Labs Inc. (TSXV-listed, formerly Miza III Ventures), with NeuroThera subsequently acquiring ~54% of CliniQuantum in 2026. The company divested MitoCareX (cancer therapeutics) to N2OFF for US$700,000 plus equity, executed two 1-for-9 reverse stock splits (2025 and 2026), and reported negative stockholders' equity of ~US$81,000 as of June 30, 2025, triggering a Nasdaq listing non-compliance notice. Operations are supported by a 1–10 employee base, cumulative disclosed equity raises of ~US$16.3 million (2022–2023), and leadership under Chairman Itschak Shrem, CEO/CFO Oz Adler, President Amitay Weiss, and CTO Dr. Adi Zuloff-Shani.
SciSparc firmographics
Firmographics- Name
- SciSparc
- Legal name
- SciSparc Ltd.
- Website
- https://investor.scisparc.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SciSparc Ltd. is an Israeli clinical-stage pharmaceutical company (NASDAQ: SPRC) developing cannabinoid-based drug candidates — SCI-110, SCI-210, and SCI-160 — for neurological, autism, and pain indications, with CannAmide nutraceutical sales in Canada and recent expansion into MUSE GERD devices and CliniQuantum quantum-simulation software via its NeuroThera Labs subsidiary.
- Ownership category
- akta.pro rank
SciSparc industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where SciSparc is headquartered
LocationHeadquarters
- HQ city
- Giv'atayim
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
SciSparc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Drug Development: SciSparc develops proprietary cannabinoid-based drug candidates through clinical trials. Revenue will come from drug approvals and commercialization, with potential for partnership or licensing deals.
- Nutraceutical Products: CannAmide product sold as a supplement in the nutraceuticals market with Health Canada product license.
- Medical Device Commercialization: Commercialization of MUSE endoscopic system for GERD treatment targeting North America, Europe, and Latin America markets.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels2 records
SciSparc product offering
Product offeringCore offering
SciSparc is a clinical-stage pharmaceutical company developing proprietary cannabinoid-based drug candidates (SCI-110, SCI-210, SCI-160) targeting neurological disorders (Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's, Autism) and chronic pain. The company also sells CannAmide, a 400mg PEA oral supplement, in Canada's nutraceutical market under Health Canada license. Through acquisitions, SciSparc has expanded into medical devices (MUSE endoscopic system for GERD) and quantum simulation platforms for clinical trial analysis.
Product overview
SciSparc is a clinical-stage pharmaceutical company developing proprietary drug candidates targeting neurological and pain conditions. The company operates two main proprietary drug platforms: SCI-110 combines Dronabinol (FDA-approved THC) with the proprietary CannAmide formulation for CNS disorders including Tourette Syndrome and Alzheimer's; SCI-210 combines CBD with CannAmide for Autism Spectrum Disorder and Status Epilepticus. The company also develops SCI-160, a synthetic CB2 receptor agonist for pain treatment. Beyond pharmaceuticals, SciSparc offers CannAmide as a nutraceutical product (400mg tablets) through its subsidiary SciSparc Nutraceuticals, and has expanded into medical devices through acquisition of the MUSE endoscopic system for GERD treatment.
Differentiator
Problem solved
Functional benefit
Brands
- CannAmide: Proprietary palmitoylethanolamide (PEA) oral formulation for reduction of chronic pain and inflammation. Available in tablet form with 400mg active pharmaceutical ingredient. Designated product license from Health Canada for sale as supplement.
Products and services
- SCI-110
Quantifiable outcome
- Targeting Tourette syndrome market projected to reach $3.38 billion by 2030
- +1 more outcomes
Companies that use SciSparc
Customer profileSegments5 records
Ideal customer profiles3 records
SciSparc technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
SciSparc partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Clearmind Medicine Inc.coreCollaboration with Clearmind Medicine on combination therapies using MEAI (Clearmind's proprietary 5-methoxy-2-aminoindane) with PEA (NeuroThera's proprietary CannAmide). Joint development of therapies for depression, binge behavior disorders, obesity, and fatty liver disease. Includes international patent applications and ongoing clinical development.
- CliniQuantum Ltd.coreNeuroThera Labs (75% owned by SciSparc) acquired approximately 54% interest in CliniQuantum, an Israeli technology company developing quantum simulation platform for clinical trial data analysis. Deal valued at approximately $9.46 million through share issuance. Includes earn-out payments up to $2.5 million tied to patent and fundraising milestones over three years.
- Xylo Technologies Ltd.coreAcquisition of MUSE system IP portfolio including patents, trademarks, and intellectual property rights for endoscopic systems and medical cameras. SciSparc issued shares representing 19.99% of outstanding share capital as consideration. Enables entry into GERD device market.
- NeuroThera Labs Inc.coreSciSparc acquired controlling interest of approximately 75% in NeuroThera Labs (formerly Miza III Ventures Inc.), a publicly traded company on TSX Venture Exchange in Canada. SciSparc transferred its clinical-stage pharmaceutical portfolio and 51% equity in SciSparc Nutraceuticals to NeuroThera. Deal valued at approximately $11.6 million. SciSparc received 63.3 million shares, 4 million warrants, and up to 48 million contingent rights.
- N2OFF Inc.minorSale of majority-owned subsidiary MitoCareX to N2OFF for $700,000 and 40% equity stake. MitoCareX focused on cancer therapeutics using computational platform and molecular screening systems. Transaction closed October 20, 2025.
- Miza III Ventures Inc.coreSciSparc agreed to acquire controlling stake by transferring pharmaceutical assets and 51% equity stake for approximately $11.6 million. Deal finalized around October 22, 2025 with Miza rebranding as NeuroThera Labs Inc.
- Quantum X Labs Ltd.coreCliniQuantum holds exclusive worldwide license agreement with Quantum X Labs Ltd. for patented quantum Monte Carlo methods for identifying patient subpopulations in clinical trials, sourced from Ramot at Tel Aviv University.
Scale indicators11 records
Recent moves7 records
Expansion highlights6 records
SciSparc competitors and assessment
Company assessmentDirect peers
- Corbus Pharmaceuticals: Clinical-stage pharmaceutical company developing cannabinoid-derived therapeutics, including CB2-targeting candidates. Closely comparable to SciSparc's SCI-110 and SCI-160 programs in mechanism and stage.
- Zynerba Pharmaceuticals: Develops transdermal cannabinoid therapies for CNS indications including Fragile X syndrome and autism spectrum disorder — directly comparable to SciSparc's SCI-210 Autism Spectrum Disorder program.
- Anavex Life Sciences: Clinical-stage CNS specialty pharma developing therapies for Alzheimer's disease, Rett syndrome, and Parkinson's — directly comparable to SciSparc's neurological and rare-disease CNS pipeline targeting similar indications.
- Marinus Pharmaceuticals: Specialty neurology pharmaceutical company developing ganaxolone for rare seizure disorders including CDKL5 deficiency disorder and Status Epilepticus — directly overlapping with SciSparc's SCI-210 Status Epilepticus program.
- EndoGastric Solutions: Commercial-stage medical device company developing the EsophyX endoscopic system for GERD treatment — directly comparable to SciSparc's MUSE system as a competing endoscopic GERD device in the same $3B+ market.
- Bionomics Limited: Clinical-stage CNS specialty pharmaceutical company developing therapies for anxiety, PTSD, and cognitive disorders — a comparable size, stage, and CNS specialty focus to SciSparc's clinical pipeline.
Broad incumbents
- Jazz Pharmaceuticals (GW Pharmaceuticals legacy): Markets Epidiolex, the first FDA-approved CBD drug for epilepsy, and acquired GW Pharmaceuticals. Represents the most established large-cap analog in cannabinoid-based neurology therapeutics, validating the regulatory pathway SciSparc is pursuing.
- Axsome Therapeutics: Commercial-stage CNS specialty pharma with FDA-approved therapies for migraine and depression — a relevant benchmark for SciSparc's CNS specialty strategy and an example of a successful clinical-to-commercial transition in this category.
Emerging players
- Mind Medicine (MindMed): Clinical-stage psychedelic- and cannabinoid-inspired therapeutics company targeting CNS conditions including anxiety and ADHD. Comparable to SciSparc's cannabinoid-based CNS approach but with overlapping psychedelic adjacency.
- Clearmind Medicine: Clinical-stage psychedelic-derived pharmaceutical company and SciSparc's active co-development partner on MEAI+PEA combination therapies for depression, binge behavior, obesity, and MASLD. Strong strategic and mechanistic overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SciSparc social profiles
Digital presenceSciSparc financial estimates
Financial estimateRevenue estimate
Valuation estimate
SciSparc leadership team
Management profileNumber of profiles
Profiles4 records
SciSparc subsidiaries and ownership
Company hierarchySubsidiaries4 records
SciSparc funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SciSparc M&A and investment
M&A and investmentM&A1 record
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SciSparc
What does SciSparc do?
SciSparc is a clinical-stage pharmaceutical company developing proprietary cannabinoid-based drug candidates (SCI-110, SCI-210, SCI-160) targeting neurological disorders (Tourette Syndrome, Obstructive Sleep Apnea, Alzheimer's, Autism) and chronic pain. The company also sells CannAmide, a 400mg PEA oral supplement, in Canada's nutraceutical market under Health Canada license. Through acquisitions, SciSparc has expanded into medical devices (MUSE endoscopic system for GERD) and quantum simulation platforms for clinical trial analysis.
Is SciSparc a public or private company?
SciSparc is a public company. It is classified as public and is currently operating.
When was SciSparc founded?
SciSparc was founded in 2020. It employs 1 to 10 people.
Where is SciSparc based?
SciSparc is headquartered in Giv'atayim, Israel, in the Middle East region.
How does SciSparc make money?
Three revenue lines are on record. Pharmaceutical Drug Development is the primary driver. The others are nutraceutical Products and medical Device Commercialization.
Who are SciSparc's main competitors?
Direct peers on record are Corbus Pharmaceuticals, Zynerba Pharmaceuticals, Anavex Life Sciences, Marinus Pharmaceuticals, EndoGastric Solutions and Bionomics Limited. Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals legacy) and Axsome Therapeutics. Emerging players are Mind Medicine (MindMed) and Clearmind Medicine.
Does SciSparc have an API?
No public API is recorded for SciSparc.
What industry is SciSparc in?
SciSparc's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.